Name | Recombinant Human TGF-beta RIII Protein |
---|---|
Supplier | R&D Systems |
Catalog | 242-R3 |
Category | Protein |
Prices | $509.00 |
Sizes | 100 µg |
Species Reactivities | Human |
Nature | Recombinant |
Source | Mouse myeloma cell line, NS0-derived Gly21-Asp781 |
Purity | >90%, by SDS-PAGE under reducing conditions and visualized by silver stain |
Bioactivity | Measured by its ability to inhibit TGF-beta 2 activity on HT‑2 mouse T cells. Tsang, M. et al . (1995) Cytokine 7 :389. The ED 50 for this effect is 20-50 ng/mL in the presence of 0.4 ng/mL of rhTGF-beta 2. |
Endotoxin | <0.10 EU per 1 μg of the protein by the LAL method. |
SwissProt/Accession | AAA67061.1 |
Gene | TGFBR3 |
Sequence | Gly21 |
Supplier Page | Shop |
Olsen OE, Wader KF, Misund K, Vatsveen TK, Ro TB, Mylin AK, Turesson I, Stordal BF, Moen SH, Standal T, Waage A, Sundan A, Holien T. Blood Cancer J. 2014 Mar 21;4:e196.
Graham JR, Chamberland A, Lin Q, Li XJ, Dai D, Zeng W, Ryan MS, Rivera-Bermudez MA, Flannery CR, Yang Z. PLoS One. 2013 Sep 11;8(9):e74094.
Florio P, Ciarmela P, Reis FM, Toti P, Galleri L, Santopietro R, Tiso E, Tosi P, Petraglia F. Eur J Endocrinol. 2005 Feb;152(2):277-84.
Bandyopadhyay A, Zhu Y, Malik SN, Kreisberg J, Brattain MG, Sprague EA, Luo J, Lopez-Casillas F, Sun LZ. Oncogene. 2002 May 16;21(22):3541-51.
Rosado E, Schwartz Z, Sylvia VL, Dean DD, Boyan BD. Biochim Biophys Acta. 2002 Jun 12;1590(1-3):1-15.